NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients

CompletedN/A

Sponsor: Pfizer

Conditions: ALK-positive Non-small-cell Lung Cancer

Interventions: Lortlatinib

Countries: Japan

To evaluate the clinical real world outcomes of lorlatinib in second/later line setting anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) to TKI sequence sequence treatment after failure of alectinib as a first-line treatment in Japanese ALK positive non-small cell lung cancer (NSCLC).

Eligibility overview

Sex: ALL

Age: 20 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Histologically or cytologically confirmed NSCLC, with any tumor, node and metastasis (TNM) stage.
* Confirmed ALK gene rearrangement by any validated test.
* Confirmed the treatment with alectinib in the first line setting as systemic therapy in the medical record.
* Confirmed the start treatment with lorlatinib as the second/later-line therapy from 1st May 2019 to 31st December 2020.

Exclusion Criteria:

-Participating on any clinical trials of which final results has not yet been reported during the study period.

Locations (16)

Nagoya, Aichi-ken, Japan
Toyoake, Aichi-ken, Japan
Yokohama, Kanagawa, Japan
Kurashiki, Okayama-ken, Japan
Hirakata, Osaka, Japan
Osaka, Osaka, Japan
Sakai-shi, Osaka, Japan
Sayama, Osaka, Japan
Sunto-gun, Shizuoka, Japan
Shimotsuke, Tochigi, Japan
Bunkyo-ku, Tokyo, Japan
Iwakuni, Yamaguchi, Japan
Ube, Yamaguchi, Japan
Koto-ku, Tokyo, Japan
Tokyo, Japan
Toyama, Japan